PDCD1 and neoplasm: In the immunotherapy domain, Pierini et al., reported that HER2-CAR-M reprogrammed the TME, enhancing CD8+ T cell infiltration, and sensitising tumours to PD-1 checkpoint blockade in vivo (36).